Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total revenue is generated in the United States.
| Website: | www.jnj.com |
| Email: | invest@surgeenergy.ca |
| Main Phone: | +1 732 524-0400 |
| Address: | One Johnson and Johnson Plaza |
| Address 2: | Suite 2100 |
| State: | NJ |
| City / Town: | New Brunswick |
| Country: | US |
| Postal Code: | 08933 |
| Exchange: | NYE |
| CEO: | Alex Gorsky |
| Employees: | 132200 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The charges against J&J are part of an action to recover $2 billion in insurance premium overcharges for defrauded New Yorkers.
Most investors spend their time looking for the next Amazon or Apple. I have a different suggestion.
The promise to play by established rules underlines a highly politicized debate over what action is needed to rein in COVID-19 quickly and to jumpstart global business and trade.
“One of the potential dangers if you prematurely let a vaccine out is that it would make it difficult, if not impossible, for the other vaccines to enroll people in their trial,” Fauci said.
J&J is paying $52.50 per share for Momenta and its pipeline of autoimmune disease therapy candidates.
The company said it would consider "challenge trials," whereby healthy volunteers would be injected with the coronavirus, if there aren't enough patients for final trials.
More than 170 nonprofit groups on Wednesday called for J&J to stop selling its talc-based Johnson’s Baby Powder world-wide, citing concerns that it contains cancer-causing asbestos.
The world’s biggest cosmetics company will remove words referencing “white,” “fair” and “light” from its skin-evening products, a spokeswoman said on Friday, in the face of growing social media criticism.
A Missouri appeals court rejected J&J's bid to toss a jury verdict in favor of women who blamed their ovarian cancer on the company's baby powder and other talc products.
The acceleration should enable J&J to take part in the massive clinical trials program planned by the U.S. government, which aims to have an effective vaccine by year end.
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total revenue is generated in the United States.
| Website: | www.jnj.com |
| Email: | invest@surgeenergy.ca |
| Main Phone: | +1 732 524-0400 |
| Address: | One Johnson and Johnson Plaza |
| Address 2: | Suite 2100 |
| State: | NJ |
| City / Town: | New Brunswick |
| Country: | US |
| Postal Code: | 08933 |
| Exchange: | NYE |
| CEO: | Alex Gorsky |
| Employees: | 132200 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The charges against J&J are part of an action to recover $2 billion in insurance premium overcharges for defrauded New Yorkers.
Most investors spend their time looking for the next Amazon or Apple. I have a different suggestion.
The promise to play by established rules underlines a highly politicized debate over what action is needed to rein in COVID-19 quickly and to jumpstart global business and trade.
“One of the potential dangers if you prematurely let a vaccine out is that it would make it difficult, if not impossible, for the other vaccines to enroll people in their trial,” Fauci said.
J&J is paying $52.50 per share for Momenta and its pipeline of autoimmune disease therapy candidates.
The company said it would consider "challenge trials," whereby healthy volunteers would be injected with the coronavirus, if there aren't enough patients for final trials.
More than 170 nonprofit groups on Wednesday called for J&J to stop selling its talc-based Johnson’s Baby Powder world-wide, citing concerns that it contains cancer-causing asbestos.
The world’s biggest cosmetics company will remove words referencing “white,” “fair” and “light” from its skin-evening products, a spokeswoman said on Friday, in the face of growing social media criticism.
A Missouri appeals court rejected J&J's bid to toss a jury verdict in favor of women who blamed their ovarian cancer on the company's baby powder and other talc products.
The acceleration should enable J&J to take part in the massive clinical trials program planned by the U.S. government, which aims to have an effective vaccine by year end.
| Last Price 145.10 | Change $ -4.08 | Change % -2.73 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open 147.58 | High 147.93 | Low 142.96 | Prev Close 149.18 |
| Last Trade | Volume 7.6 mi | 52 Wk Hi 157.00 | 52 Wk Low 109.17 |
| Market Cap 382 bi | Ex-Div Date | Div Rate 4.04 | Yield 2.7080 |
| Shares 2,632,823,475.00 | EPS (TTM) 5.69 | PE Ratio 26.20 | Exchange NYSE |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 51 |
| Number of Buys | 0 | 28 |
| Number of Sells | 0 | 23 |
| Net Activity | 0 | 258349 |
| Last 10 Buys | Shares |
|---|---|
| Charles O. Prince | 1,000 |
| Charles O. Prince | 1,000 |
| Charles O. Prince | 1,000 |
| William D. Perez | 1,000 |
| William D. Perez | 1,000 |
| William D. Perez | 1,000 |
| William D. Perez | 1,000 |
| William D. Perez | 1,000 |
| William D. Perez | 1,000 |
| William D. Perez | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Paulus Stoffels | 1,000 |
| Paulus Stoffels | 1,000 |
| Dominic J. Caruso | 1,000 |
| Joaquin Duato | 1,000 |
| Gary J. Pruden | 1,000 |
| Ronald A. Kapusta | 1,000 |
| Paulus Stoffels | 1,000 |
| Michael H. Ullmann | 1,000 |
| Dominic J. Caruso | 1,000 |
| Ronald A. Kapusta | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 161 | 161 | 161 | 161 |
| Low Target Price Estimate | 110 | 110 | 110 | 110 |
| Mean Target Price Estimate | 146.07 | 146.07 | 146.07 | 146.07 |
| Standard Deviation | 12.86 | 12.86 | 12.86 | 12.86 |
| Date of Most Recent Estimate | 05/17/18 | 05/17/18 | 05/17/18 | 05/17/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| SD | Specialized Disclosure Report | 18 | 2018-05-23 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-05-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-05-02 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 98 | 2018-05-01 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-04-30 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-04-30 |
| 8-K | Report of unscheduled material events or corporate changes. | 20 | 2018-04-17 |
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-03-20 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-15 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 |
| Moderate Buy | 2 | 2 | 2 | 2 |
| Hold | 6 | 6 | 6 | 6 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 2 | 2 | 2 | 2 |
| Mean Rec. | 2.22 | 2.22 | 2.22 | 2.22 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait